Evotec AG and MaRS Innovation have identified the first project to be developed under their LAB150 partnership.   This comes after the signing a collaboration agreement in September 2017. The project aims to develop kallikrein-targeting compounds as novel topical drugs for the rare but severe inflammatory skin disease ‘Netherton Syndrome’ as well as the broader disorder atopic dermatitis. Skin kallikreins are expressed in the outer layer of the human skin and represent an attractive targ...